Rapamycin and Longevity in Germany

Rapamycin (sirolimus) is a prescription immunosuppressant, not a supplement. It is the most reliable life-extender in animal studies (median lifespan +9% to +13% in mice ^[1]) because it blocks the mTOR nutrient switch, but it carries real immune-suppressing risks and has no proven longevity benefit in humans yet.

Here is the short version. Rapamycin (also called sirolimus, same molecule, two names) is a prescription drug, not a supplement. It came from a soil bacterium called Streptomyces hygroscopicus, found on Easter Island (Rapa Nui). The FDA approved it in 1999 as the immune-suppressing drug Rapamune (made by Wyeth-Ayerst, then Pfizer after Pfizer bought Wyeth in October 2009). Europe gave it an EU-wide green light on 13 March 2001 ^[6]. Its first job was simple: calm the immune system down after a kidney transplant.

So how does it work? Rapamycin blocks a protein switch called mTOR (think of it as a sensor that checks whether your cells are flush with nutrients), and one version in particular, mTORC1. That switch runs cell growth, protein building, and autophagy (your cells cleaning out their own junk).

Why the longevity crowd is so into it: in animals, nothing else stretches lifespan this reliably. A 2009 paper in Nature from the NIH Interventions Testing Program found that mice on encapsulated rapamycin, started late at 600 days of age, lived longer: median lifespan went up +9% in males and +13% in females ^[1]. Other rodent ITP runs and separate cohorts point the same way, and so does work on TOR (the animal version of mTOR) in fruit flies (Drosophila) and roundworms (C. elegans). The effect shows up across species, even if it stays modest and strain-dependent in the tiny invertebrates.

One thing to get straight: rapamycin is not a longevity supplement. It genuinely suppresses the immune system and brings other side effects, so any off-label use carries real risk.

This guide is not medical advice.

mTOR matters for aging because it is the nutrient switch that decides whether cells grow or repair. Keep it switched on for too long and cells stop cleaning house: autophagy stalls, senescent cells pile up, and aging seems to speed up. Rapamycin turns mTOR down directly, which is why it extends lifespan in mice (median +9% to +13% ^[1]).

The whole mTOR longevity story rests on one simple chain of logic:

1. mTOR is an old nutrient sensor. It flips on whenever real food is around. Eat a lot, and it stays switched on.
2. Keep mTOR high for too long and aging seems to speed up. It shuts down autophagy (the cell's cleanup crew) and lets zombie cells pile up. Those are old cells that refuse to die and keep stoking low-grade inflammation.
3. Anything that turns mTOR down stretches animal lifespan. Eat less, fast, or take rapamycin.
4. Rapamycin is the most direct way to turn it down. You set a dose schedule instead of having to white-knuckle a diet for the rest of your life.

What the mouse studies found (NIH Intervention Testing Program):

• Give older mice rapamycin and they live longer. Median lifespan went up about 9% in males and 13% in females, and the longest-lived 10% (the 90th percentile) gained about 9% in males and 14% in females, even when treatment started late ^[1]. That popular 14% figure for females is the 90th-percentile number, basically the maximum lifespan; the matching median is 13%.
• The effect held up across different mouse strains. That is a big deal. Most rodent longevity wins quietly collapse the moment you swap in a different genetic background.
• More dose, bigger effect.

The honest open questions for people:

• We already age 30 to 50 times slower than mice. So a 15 percent gain on a 2-year mouse life does not magically become 15 percent on 80 human years.
• Damping the immune system at age 70, while normal infections circulate, is a real and ongoing worry even at weekly doses.
• Daily versus once a week? Newer protocols use low weekly doses to soften the immune hit, but the evidence behind that schedule is still thin.

No human trial has shown rapamycin extends life or healthspan. The biggest longevity study so far, PEARL (2025), missed its main endpoint of cutting visceral fat, with only secondary wins in women on 10 mg ^[5]. The human evidence is far thinner than the animal record and rests on short trials of stand-in markers.

Here is where the hype meets reality. The human data on rapamycin for longevity is far thinner than the animal record. Most of it comes from short trials that measure stand-in markers, not how long people actually live.

The trials that aimed at longevity directly:

• The PEARL study (run by AgelessRx/Lifespan.io, trial ID NCT04488601, published April 2025 in Aging (Albany NY)). Matt Kaeberlein commented on it from the outside but was not a formal advisor. It was a 48-week randomized, placebo-controlled trial in healthy adults, testing rapamycin at 5 mg and 10 mg weekly. One catch: they used compounded rapamycin, which reports say your body absorbs less well than brand-name Rapamune, and the authors flag this as a real limitation. The endpoint they had committed to up front was a drop in visceral fat (the deep belly fat around your organs) on a DEXA scan. They did not hit it. The wins that did show up were secondary, and only in the women taking 10 mg: more lean tissue and lower self-reported pain ^[5].
• The lower-dose immune trials. Two related studies ran in older adults. The 2014 one (in Sci Transl Med) tested everolimus, a rapamycin cousin also called RAD001, on its own, with doses from 0.5 mg daily up to 20 mg weekly ^[2]. The 2018 one (also Sci Transl Med) tested RTB101 by itself and a low-dose RTB101 plus everolimus 0.1 mg combo at various doses. Only one arm, RTB101 at 10 mg once daily, hit the goal it had set out in advance; the higher doses and the combo did not ^[3]. A follow-up phase 3 trial in Lancet Healthy Longevity (2021) failed to repeat the earlier phase 2b benefit, and that killed the RTB101 immune-boosting program ^[4]. Worth stressing: this flop is about RTB101, not rapamycin itself.

What we see in transplant patients:

• People on rapamycin after a transplant get less skin cancer, and maybe fewer of some other cancers too. But those numbers come from people who were already immune-suppressed for other reasons ^[8].
• So it does not map cleanly onto longevity use in an otherwise healthy adult.

The side effects you see most at longevity doses (5 to 6 mg per week):

• Mouth ulcers. By far the most common gripe. A topical dexamethasone mouthwash can help.
• Occasional signs of a softened immune response, like minor infections that linger or come back more often
• Higher blood fats (triglycerides and LDL)
• Higher blood sugar
• Proteinuria (protein leaking into urine, a classic kidney issue in transplant patients). Rare at weekly longevity doses, but still tracked with a urine ACR test.
• Slower wound healing. Pause rapamycin at least two weeks before any planned surgery and only restart once the wound has fully healed.
• Pneumonitis or interstitial lung disease (inflammation in the lungs). Uncommon, but it is listed in the official drug label (the SmPC). A new dry cough or shortness of breath needs urgent checking.
• Interactions with a lot of drugs, all running through one liver enzyme called CYP3A4

Hard nos and serious cautions:

• Pregnancy and breastfeeding. In animal studies rapamycin harms the developing fetus (fetal death and lower fetal weight; no structural malformations were seen), and based on those findings and how the drug works, it can harm a human fetus too. You need effective contraception during treatment and for 12 weeks after you stop.
• Live vaccines (yellow fever, MMR, varicella, nasal flu) are off-limits while on rapamycin, so finish any travel shots you need before you start, or during a planned break.
• Recent or upcoming surgery. See the wound-healing note above.
• Active infection or an open wound. Pause until it clears.

What we genuinely still do not know:

• Whether it is safe over 10-plus years in healthy adults
• The best dose and schedule
• Who actually benefits

Short answer: yes, rapamycin (sirolimus) is an approved medicine in Germany, but only for a few specific jobs:

• Calming the immune system after a kidney transplant
• Lymphangioleiomyomatosis (LAM, a rare lung disease)
• Some vascular malformations (off-label)

Longevity is not on that list. Any prescription written for it counts as off-label. That is legal, but it puts more liability on the doctor and means they have to counsel you more carefully than usual.

What this looks like in real life:

• Your statutory health insurance won't pay. It only covers rapamycin for approved uses, so for longevity you cover 100 percent yourself.
• The cost adds up fast. At the official pharmacy price (Apothekenverkaufspreis, AVP), a Rapamune 1 mg tablet runs about €11.85 (Lauer-Taxe / gelbe-liste.de spot-check, 2026; verify before publication). At 5 to 6 mg per week, that lands around €240 to 310 per month. You only get into the cheaper €60 to 150 per month range with parallel imports or compounded sirolimus from a compounding pharmacy.
• Finding a prescriber is the hard part. You need a doctor willing to go off-label, and in Germany very few practices do. The US has online services for this. Germany does not.
• Advertising rules (HWG). Promoting rapamycin with longevity claims is not allowed.

What about ordering it from outside the EU/EEA (India, Turkey)? Mailing prescription medicines from non-EU/EEA countries to private individuals is banned under §73 of the German medicines act (Arzneimittelgesetz, AMG). This is not a grey zone ^[7]. German Customs (Zoll) checks international mail all the time and seizes these parcels, and recipients can face warnings, fines, and in some cases a criminal investigation. There is a separate, narrow exception: a traveller may carry up to a 3-month supply of a non-narcotic prescription drug in their own luggage when entering Germany. That does not cover anything sent by post. And even if a package slips through, you get zero quality control. Not recommended.

For NMN and other grey-zone questions, see the NMN Germany guide.

Talk to a doctor who knows rapamycin and will monitor you with regular labs, never your GP without specific training. Come with your current markers, your medication list, and a clear sense of the risk you will carry. Good prescribers ask their own questions and agree on stop criteria up front; anyone who prescribes without any of that is the wrong partner.

If you are seriously weighing rapamycin for longevity, there is really only one sensible route: a doctor who knows the drug and will actually monitor you.

This guide gives no dosing advice. The eligibility points and lab numbers below are things to talk through with the doctor who would prescribe it, not thresholds you manage on your own. Off-label rapamycin needs individual medical supervision and your informed consent.

Green-light and red-light signals:

• Probably not a fit if you get infections often, have surgery planned in the next 6 months, run an uncontrolled HbA1c (a 3-month blood-sugar average) above 6.5%, have LDL-C (your bad cholesterol) above 160 mg/dL, have a weakened immune system, are being treated for active cancer, are pregnant, nursing, or planning to get pregnant within 12 months, or are under 45 without a specific fast-aging profile.
• Possibly a fit if you are 55 or older, metabolically healthy, with LDL-C and HbA1c in range, no surgeries on the calendar, willing to pause for any acute infection, have a doctor available for quarterly checks, and you go in knowing this is off-label and the evidence is still light.

Which doctor to ask:

• Internal medicine specialists with a prevention or longevity focus
• Longevity private practices in Munich, Berlin, Hamburg, Frankfurt
• Not your regular GP without specific training

Finding a prescriber in DACH. Very few German Hausärzte will write an off-label rapamycin script, so your better bet is internal-medicine doctors who hold the Zusatzbezeichnung Naturheilverfahren or Ernährungsmedizin (the two formal BÄK add-on qualifications that fit here; note that "Präventivmedizin" is a continuing-education course, not a Zusatzbezeichnung), or dedicated longevity private practices in Munich, Berlin, Hamburg, Frankfurt, Vienna, Zurich. To search, try arzt-auskunft.de with the right Zusatzbezeichnung filter, or the Ärztekammer Bayern, ÖÄK, or FMH directories. Plan for €200 to 500 for a first self-pay (Selbstzahler) visit.

The CYP3A4 interactions worth knowing (these are everyday traps). Remember that CYP3A4 is the liver enzyme that clears rapamycin, so anything that blocks it pushes your levels up, and anything that revs it up drops them. Do not pair rapamycin with grapefruit, juice or fruit (it pushes levels up). Skip St. John's wort and rifampicin too (both rev the enzyme and drop your levels, with rifampicin the textbook example, relevant if you are on TB treatment or some staph prophylaxis). Also steer clear of clarithromycin or erythromycin, ketoconazole or itraconazole, diltiazem or verapamil. Many statins need a dose tweak alongside it. Always hand your pharmacist and doctor a full list of what you take, including over-the-counter and herbal stuff.

The lab schedule if you are on off-label rapamycin:

• At baseline: a full blood count (CBC), a metabolic panel (CMP), fasting lipids, HbA1c, fasting glucose, lipase, a urine ACR (checks for protein in urine), vitamin D, blood pressure, and a TB screen.
• At week 4: recheck the blood count, metabolic panel, fasting glucose, lipids, and lipase.
• Then every quarter: the same labs.
• When to stop: a neutrophil count (ANC, a type of white blood cell) below 1.5, new protein in the urine, triglycerides above 500, HbA1c climbing more than 0.5% above your baseline, mouth ulcers that won't quit despite dose changes, or any active infection (pause until it clears).

A note on women's health. Rapamycin (sirolimus) used to sit in the old FDA Pregnancy Category C, because animal studies showed harm to the developing fetus (fetal death and lower fetal weight, not structural malformations). The FDA scrapped that A/B/C/D/X letter system in 2015 under the Pregnancy and Lactation Labeling Rule (PLLR), so today's Rapamune label uses a plain-language 'Risk Summary' saying the drug can harm a fetus, based on the animal data and how it works. You need effective contraception during treatment and for 12 weeks after stopping. Not for nursing mothers. There is no longevity reason that justifies rapamycin in pregnancy or breastfeeding, full stop.

Before you go in, get clear on:

• Your current markers (blood panel, heart and blood vessel risk, metabolic profile)
• Any drugs you take that clash with rapamycin (the CYP3A4 list)
• Any current or chronic infections
• How much risk you are personally willing to carry

Fair questions to put to the doctor:

1. Do you know the current longevity data on rapamycin?
2. Are you willing to prescribe off-label and document it properly?
3. Which lab values would you track?
4. How often should I come back for check-ins?
5. What would make you stop treatment?

A doctor who brushes off these questions is the wrong partner. So is one who will prescribe without asking any of their own.